Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Has Consensus Target Price of $683.64 According to Brokerages

Key Points

• Analysts rate Thermo Fisher a “Moderate Buy”: 23 of 29 covering brokerages recommend buying and two recommend a strong buy; the average 12-month price target is $683.64.
• The company beat quarterly estimates, reporting EPS of $6.68 versus $6.40 expected and revenue of $12.14 billion, up 9.1% year over year.
• Thermo Fisher authorized up to $5 billion in share repurchases and declared a quarterly dividend of $0.47 per share, equivalent to a roughly 0.3% annual yield.

Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) has been assigned an average rating of "Moderate Buy" from the twenty-nine brokerages that are currently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating, twenty-three have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $683.64.

TMO has been the topic of a number of research analyst reports. Guggenheim assumed coverage on Thermo Fisher Scientific in a research report on Thursday, October 15th. They set a "buy" rating and a $740.00 target price on the stock. Wall Street Zen raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday, October 3rd. Jefferies Financial Group restated a "buy" rating and set a $630.00 price target (up from $585.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. BMO Capital Markets lowered Thermo Fisher Scientific to a "market perform" rating in a research report on Wednesday, September 9th. Finally, Piper Sandler began coverage on Thermo Fisher Scientific in a research note on Wednesday, September 9th. They issued an "overweight" rating and a $510.00 price objective for the company.

Thermo Fisher Scientific Stock Up 2.7%

TMO stock opened at $694.93 on Friday. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.71. Thermo Fisher Scientific has a twelve month low of $435.27 and a twelve month high of $712.17. The company's 50 day moving average is $661.03 and its two-hundred day moving average is $554.78. The stock has a market cap of $257.48 billion, a P/E ratio of 36.65, a PEG ratio of 2.83 and a beta of 0.84.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, October 21st. The medical research company reported $6.68 EPS for the quarter, beating analysts' consensus estimates of $6.40 by $0.28. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The firm had revenue of $12.14 billion for the quarter, compared to the consensus estimate of $11.95 billion. During the same period last year, the firm posted $5.79 EPS. The company's revenue was up 9.1% on a year-over-year basis. Research analysts expect that Thermo Fisher Scientific will post 25.26 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 15th. Stockholders of record on Tuesday, December 15th will be given a dividend of $0.47 per share. The ex-dividend date is Tuesday, December 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.92%.

Insider Activity

In related news, CEO Marc Casper sold 10,000 shares of the company's stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $629.27, for a total value of $6,292,700.00. Following the completion of the sale, the chief executive officer owned 123,925 shares in the company, valued at $77,982,284.75. This represents a 7.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Shafer sold 25,500 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the sale, the executive vice president owned 20,994 shares of the company's stock, valued at approximately $12,596,400. This represents a 54.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 50,046 shares of company stock valued at $30,779,192 in the last ninety days. 0.33% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Thermo Fisher Scientific

Several hedge funds have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in Thermo Fisher Scientific in the 2nd quarter valued at $15,501,867,000. Corient Private Wealth LP purchased a new position in Thermo Fisher Scientific during the 2nd quarter worth $382,547,000. Bank of New York Mellon Corp purchased a new stake in shares of Thermo Fisher Scientific in the second quarter valued at about $1,974,561,000. Bank of America Corp DE purchased a new stake in shares of Thermo Fisher Scientific in the second quarter valued at about $1,952,930,000. Finally, Legal & General Group Plc acquired a new position in shares of Thermo Fisher Scientific during the second quarter worth about $1,122,351,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific News Summary

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: The board authorized up to $5 billion in share repurchases, replacing the prior authorization, which had $1 billion remaining. The program has no expiration date and could support per-share results and signal confidence in the business. Thermo Fisher Scientific Authorizes $5 Billion of Share Repurchases
• Positive Sentiment: Recent quarterly results were better than expected: EPS of $6.68 beat the $6.40 consensus, while revenue of $12.14 billion exceeded estimates and increased 9.1% year over year. Thermo Fisher Scientific Authorizes $5 Billion Share Buyback after Upbeat Earnings
• Positive Sentiment: Thermo Fisher declared a quarterly dividend of $0.47 per share, payable January 15, 2027. The annualized dividend is $1.88 per share, though the indicated yield is modest at about 0.3%. Thermo Fisher Scientific Announces Quarterly Dividend
• Positive Sentiment: The company introduced value-priced AmpSure qPCR master mixes, adding an offering aimed at labs seeking dependable testing performance at lower cost. Thermo Fisher Introduces AmpSure Universal qPCR Master Mixes
• Neutral Sentiment: Market research reports point to growth in oligonucleotide synthesis, mRNA manufacturing, protein labeling and Q-TOF mass spectrometry—areas related to Thermo Fisher’s markets. These industry forecasts suggest potential demand tailwinds, but do not provide company-specific sales or earnings guidance. Global Oligonucleotide Synthesis Services Market Report 2026

About Thermo Fisher Scientific

Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research.

The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.